Breaking News Instant updates and real-time market news.

GENE

Genetic Technologies

$3.54 /

-0.06 (-1.67%)

08:40
07/26/21
07/26
08:40
07/26/21
08:40

Genetic Technologies gives update on product overview, regulatory progress

GTG's Polygenic Risk Score products under development will ultimately be offered as part of the GeneType Multitest, which will provide risk assessment for greater than 70% of all morbidities including Breast Cancer, Colorectal Cancer, Cardiovascular Disease, Type 2 Diabetes, Melanoma and Prostate Cancer. The Multitest will leverage the foundational IP granted under US Patent 7,127,355 - 'Methods for Genetic Analysis'. Recent advances in the Prostate Cancer and Melanoma Tests have identified informative polygenic risk scores that could enhance predictability with the Company intending to release initial findings by the end of CY21. The overall strategy for the Multitest is focused on precise risk assessments for the most common preventable diseases. Future iterations of the test will include the Company's germline hereditary cancer testing products which are currently under development. GeneType Breast Cancer and Colorectal Cancer Screening and Germline Testing Platform: GTG continues to progress the development of its Germline Testing division for hereditary testing. The initial BRCA and Lynch Syndrome tests, that align with GTG's GeneType products in market for Breast Cancer and Colorectal Cancer respectively, are anticipated to launch by the end of CY21. These hereditary tests increase coverage from 85% under standalone polygenic risk up to 100%1 of known risk coverage when combined with GTG's PRS testing. BRCA and Lynch Syndrome tests also have existing reimbursement codes, which provides a clear pathway to monetization and an opportunity to bundle with their associated PRS tests. The Company continues to engage in discussions with Medicare to enable the Company to secure a rebate for PRS tests conducted. This remains a longer-term objective and is expected to support distribution through the B2B channel. Predictix by Taliaz: GTG highlighted the Predictix by Taliaz product at the General Practice Conference and Exhibition in Sydney in mid-May 2021 with solid feedback and are progressing discussions on partnerships to advance the distribution and sales of the product in Australia and New Zealand. In addition, the Taliaz product will be incorporated into GTG's Multitest. Research and Publications: GTG continues to focus on publications of relevant content for submission to peer-reviewed journals.

TODAY'S FREE FLY STORIES

Initiation
1Life Healthcare initiated with a Market Perform at SVB Leerink » 07:01
09/27/21
09/27
07:01
09/27/21
07:01
ONEM

1Life Healthcare

$21.46 /

-0.98 (-4.37%)

SVB Leerink analyst Whit…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ONEM 1Life Healthcare
$21.46 /

-0.98 (-4.37%)

ONEM 1Life Healthcare
$21.46 /

-0.98 (-4.37%)

09/24/21 Piper Sandler
1Life Healthcare price target lowered to $37 from $55.50 at Piper Sandler
08/12/21 Barclays
1Life Healthcare initiated with an Overweight at Barclays
08/09/21 Baird
Baird downgrades 1Life Healthcare to Neutral on Iora overhang, lack of catalysts
08/09/21 Baird
1Life Healthcare downgraded to Neutral from Outperform at Baird
ONEM 1Life Healthcare
$21.46 /

-0.98 (-4.37%)

  • 23
    Nov
ONEM 1Life Healthcare
$21.46 /

-0.98 (-4.37%)

ONEM 1Life Healthcare
$21.46 /

-0.98 (-4.37%)

Periodicals
Credit Suisse Greensill funds to return another $400M, Bloomberg reports » 06:59
09/27/21
09/27
06:59
09/27/21
06:59
CS

Credit Suisse

$9.89 /

+0.08 (+0.82%)

Credit Suisse plans to…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CS Credit Suisse
$9.89 /

+0.08 (+0.82%)

CS Credit Suisse
$9.89 /

+0.08 (+0.82%)

09/17/21 JPMorgan
Credit Suisse price target lowered to CHF 11.30 from CHF 11.60 at JPMorgan
08/12/21 Citi
Credit Suisse removed from EMEA Focus List at Citi
07/30/21 Barclays
Credit Suisse price target raised to CHF 12.50 from CHF 12 at Barclays
07/30/21 JPMorgan
Credit Suisse price target lowered to CHF 11.60 from CHF 11.70 at JPMorgan
CS Credit Suisse
$9.89 /

+0.08 (+0.82%)

CS Credit Suisse
$9.89 /

+0.08 (+0.82%)

CS Credit Suisse
$9.89 /

+0.08 (+0.82%)

CS Credit Suisse
$9.89 /

+0.08 (+0.82%)

Hot Stocks
Asensus Surgical: Senhance system purchased by Loginov MCSC » 06:57
09/27/21
09/27
06:57
09/27/21
06:57
ASXC

Asensus Surgical

$1.87 /

-0.125 (-6.27%)

Asensus Surgical…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ASXC Asensus Surgical
$1.87 /

-0.125 (-6.27%)

ASXC Asensus Surgical
$1.87 /

-0.125 (-6.27%)

05/26/21 H.C. Wainwright
Asensus Surgical initiated with a Buy at H.C. Wainwright
ASXC Asensus Surgical
$1.87 /

-0.125 (-6.27%)

ASXC Asensus Surgical
$1.87 /

-0.125 (-6.27%)

Earnings
JinkoSolar sees Jiangxi Jinko revenue for 9 months end Sep. 30 at RMB23.6B-23.8B » 06:57
09/27/21
09/27
06:57
09/27/21
06:57
JKS

JinkoSolar

$42.35 /

-1.48 (-3.38%)

On Friday, JinkoSolar…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
JKS JinkoSolar
$42.35 /

-1.48 (-3.38%)

JKS JinkoSolar
$42.35 /

-1.48 (-3.38%)

09/16/21 Roth Capital
JinkoSolar price target lowered to $51 from $58 at Roth Capital
09/16/21 GLJ Research
GLJ sees nearly 80% downside in JinkoSolar, cuts target to $10.70
08/13/21 GLJ Research
JinkoSolar shipment into U.S. stopped by customs, says GLJ Research
07/02/21 Goldman Sachs
JinkoSolar price target raised to $27 from $25 at Goldman Sachs
JKS JinkoSolar
$42.35 /

-1.48 (-3.38%)

JKS JinkoSolar
$42.35 /

-1.48 (-3.38%)

JKS JinkoSolar
$42.35 /

-1.48 (-3.38%)

Hot Stocks
Dollar General announces planned expansion into Idaho » 06:55
09/27/21
09/27
06:55
09/27/21
06:55
DG

Dollar General

$217.71 /

-0.71 (-0.33%)

Dollar General announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
DG Dollar General
$217.71 /

-0.71 (-0.33%)

DG Dollar General
$217.71 /

-0.71 (-0.33%)

08/27/21 Raymond James
Dollar General price target raised to $260 from $235 at Raymond James
08/23/21 Deutsche Bank
Dollar General price target raised to $253 from $231 at Deutsche Bank
08/17/21 OTR Global
Dollar General downgraded to Mixed from Positive at OTR Global
07/15/21 Oppenheimer
Dollar General price target raised to $270 from $225 at Oppenheimer
DG Dollar General
$217.71 /

-0.71 (-0.33%)

DG Dollar General
$217.71 /

-0.71 (-0.33%)

DG Dollar General
$217.71 /

-0.71 (-0.33%)

DG Dollar General
$217.71 /

-0.71 (-0.33%)

Hot Stocks
JinkoSolar to invest $500M to build monocrystalline ingot, wafer facility » 06:53
09/27/21
09/27
06:53
09/27/21
06:53
JKS

JinkoSolar

$42.35 /

-1.48 (-3.38%)

JinkoSolar announced that…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
JKS JinkoSolar
$42.35 /

-1.48 (-3.38%)

JKS JinkoSolar
$42.35 /

-1.48 (-3.38%)

09/16/21 Roth Capital
JinkoSolar price target lowered to $51 from $58 at Roth Capital
09/16/21 GLJ Research
GLJ sees nearly 80% downside in JinkoSolar, cuts target to $10.70
08/13/21 GLJ Research
JinkoSolar shipment into U.S. stopped by customs, says GLJ Research
07/02/21 Goldman Sachs
JinkoSolar price target raised to $27 from $25 at Goldman Sachs
JKS JinkoSolar
$42.35 /

-1.48 (-3.38%)

JKS JinkoSolar
$42.35 /

-1.48 (-3.38%)

JKS JinkoSolar
$42.35 /

-1.48 (-3.38%)

Hot Stocks
Tyme Technologies says first patient dosed in Phase II OASIS trial » 06:51
09/27/21
09/27
06:51
09/27/21
06:51
TYME

Tyme Technologies

$1.09 /

+0.045 (+4.31%)

Tyme Technologies…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
TYME Tyme Technologies
$1.09 /

+0.045 (+4.31%)

TYME Tyme Technologies
$1.09 /

+0.045 (+4.31%)

General news
European stock markets are broadly higher » 06:50
09/27/21
09/27
06:50
09/27/21
06:50
$ECON

Economic Data

/

+

European stock markets…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

Hot Stocks
Pfizer announces start of Phase 2/3 EPIC-PEP study » 06:47
09/27/21
09/27
06:47
09/27/21
06:47
PFE

Pfizer

$43.94 /

-0.25 (-0.57%)

Pfizer announced the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
PFE Pfizer
$43.94 /

-0.25 (-0.57%)

PFE Pfizer
$43.94 /

-0.25 (-0.57%)

09/24/21 Piper Sandler
Piper confident in Opko's somatrogon approval despite BLA review delay
09/24/21 Morgan Stanley
Morgan Stanley says CDC call 'modest narrowing' of Pfizer booster recommendation
09/20/21 Citi
Citi says 'remain upbeat' on Pfizer Covid revenue despite mixed panel vote
09/17/21 Evercore ISI
Evercore ISI doesn't think FDA panel will recommend COVID-19 boosters
PFE Pfizer
$43.94 /

-0.25 (-0.57%)

PFE Pfizer
$43.94 /

-0.25 (-0.57%)

PFE Pfizer
$43.94 /

-0.25 (-0.57%)

PFE Pfizer
$43.94 /

-0.25 (-0.57%)

Recommendations
IAC could be 'big winner' if Meredith rumor true, says Benchmark » 06:47
09/27/21
09/27
06:47
09/27/21
06:47
IAC

IAC

$140.43 /

+6.795 (+5.08%)

, MDP

Meredith

$56.43 /

+11.51 (+25.62%)

Benchmark analyst Daniel…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
IAC IAC
$140.43 /

+6.795 (+5.08%)

MDP Meredith
$56.43 /

+11.51 (+25.62%)

IAC IAC
$140.43 /

+6.795 (+5.08%)

08/24/21 Citi
IAC price target lowered to $175 from $185 at Citi
08/11/21 Wells Fargo
IAC price target lowered to $160 from $280 at Wells Fargo
08/06/21 Piper Sandler
IAC price target lowered to $158 from $180 at Piper Sandler
08/06/21 Wedbush
IAC price target lowered to $177 from $193 at Wedbush
MDP Meredith
$56.43 /

+11.51 (+25.62%)

08/17/21 Citi
Meredith price target raised to $54 from $51 at Citi
08/13/21 Benchmark
Meredith price target raised to $58 from $43 at Benchmark
06/29/21 Citi
Meredith price target raised to $51 from $41 at Citi
05/03/21 Barrington
Gray creates added scale with Meredith's broadcast assets, says Barrington
IAC IAC
$140.43 /

+6.795 (+5.08%)

MDP Meredith
$56.43 /

+11.51 (+25.62%)

IAC IAC
$140.43 /

+6.795 (+5.08%)

MDP Meredith
$56.43 /

+11.51 (+25.62%)

IAC IAC
$140.43 /

+6.795 (+5.08%)

MDP Meredith
$56.43 /

+11.51 (+25.62%)

Hot Stocks
Merck says Phase 3 KEYNOTE-394 trial met primary endpoint of OS » 06:46
09/27/21
09/27
06:46
09/27/21
06:46
MRK

Merck

$73.61 /

+0.56 (+0.77%)

Merck announced that the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
MRK Merck
$73.61 /

+0.56 (+0.77%)

MRK Merck
$73.61 /

+0.56 (+0.77%)

09/23/21 Citi
Citi opens 'Positive Catalyst Watch' on Merck into Covid data
09/22/21 Goldman Sachs
Vir Biotechnology downgraded to Neutral from Buy at Goldman Sachs
09/21/21 BMO Capital
Regeneron price target raised to $706 from $669 at BMO Capital
09/21/21 Barclays
Merck faces 'compelling series' of catalysts into 2022, says Barclays
MRK Merck
$73.61 /

+0.56 (+0.77%)

MRK Merck
$73.61 /

+0.56 (+0.77%)

MRK Merck
$73.61 /

+0.56 (+0.77%)

MRK Merck
$73.61 /

+0.56 (+0.77%)

Hot Stocks
Vinco Ventures up 17% in pre-market trading at $7.42 per share » 06:44
09/27/21
09/27
06:44
09/27/21
06:44
BBIG

Vinco Ventures

$6.31 /

+0.09 (+1.45%)

Shares of Vinco Ventures…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BBIG Vinco Ventures
$6.31 /

+0.09 (+1.45%)

BBIG Vinco Ventures
$6.31 /

+0.09 (+1.45%)

BBIG Vinco Ventures
$6.31 /

+0.09 (+1.45%)

BBIG Vinco Ventures
$6.31 /

+0.09 (+1.45%)

Recommendations
Herman Miller price target lowered to $55 from $61 at Benchmark » 06:40
09/27/21
09/27
06:40
09/27/21
06:40
MLHR

Herman Miller

$41.05 /

+0.42 (+1.03%)

Benchmark analyst Reuben…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
MLHR Herman Miller
$41.05 /

+0.42 (+1.03%)

MLHR Herman Miller
$41.05 /

+0.42 (+1.03%)

06/30/21 Benchmark
Herman Miller price target raised to $61 from $50 at Benchmark
05/11/21 Berenberg
Berenberg starts Herman Miller at Buy, cites work-from-home 'dominance'
05/11/21 Berenberg
Herman Miller initiated with a Buy at Berenberg
05/10/21 Craig-Hallum
Craig-Hallum bullish on Herman Miller, initiates with a Buy
MLHR Herman Miller
$41.05 /

+0.42 (+1.03%)

MLHR Herman Miller
$41.05 /

+0.42 (+1.03%)

MLHR Herman Miller
$41.05 /

+0.42 (+1.03%)

MLHR Herman Miller
$41.05 /

+0.42 (+1.03%)

Hot Stocks
Aspen Group director Douglas Kass buys 32K share of common stock » 06:40
09/27/21
09/27
06:40
09/27/21
06:40
ASPU

Aspen Group

$5.10 /

-0.01 (-0.20%)

In a regulatory filing,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ASPU Aspen Group
$5.10 /

-0.01 (-0.20%)

ASPU Aspen Group
$5.10 /

-0.01 (-0.20%)

09/15/21 Craig-Hallum
Aspen Group price target lowered to $10 from $14 at Craig-Hallum
07/14/21 Canaccord
Aspen Group price target lowered to $13 from $14 at Canaccord
06/24/21 Canaccord
Aspen Group a good entry point following retreat from highs, says Canaccord
05/18/21 Roth Capital
Aspen Group risk/reward 'highly favorable,' says Roth Capital
ASPU Aspen Group
$5.10 /

-0.01 (-0.20%)

ASPU Aspen Group
$5.10 /

-0.01 (-0.20%)

ASPU Aspen Group
$5.10 /

-0.01 (-0.20%)

Recommendations
Mizuho sees RingCentral bearish sentiment reversing, keeps $400 target » 06:38
09/27/21
09/27
06:38
09/27/21
06:38
RNG

RingCentral

$222.09 /

-1.13 (-0.51%)

RingCentral shares are…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
RNG RingCentral
$222.09 /

-1.13 (-0.51%)

RNG RingCentral
$222.09 /

-1.13 (-0.51%)

09/08/21 Mizuho
RingCentral selloff on retirement a buying opportunity, says Mizuho
08/06/21 Mizuho
RingCentral selloff brings 'compelling buying opportunity,' says Mizuho
08/04/21 Truist
RingCentral price target lowered to $450 from $525 at Truist
08/04/21 Deutsche Bank
RingCentral price target lowered to $400 from $450 at Deutsche Bank
RNG RingCentral
$222.09 /

-1.13 (-0.51%)

RNG RingCentral
$222.09 /

-1.13 (-0.51%)

RNG RingCentral
$222.09 /

-1.13 (-0.51%)

Recommendations
Alkermes takeover thesis 'highly speculative,' says BofA » 06:35
09/27/21
09/27
06:35
09/27/21
06:35
ALKS

Alkermes

$32.09 /

+0.17 (+0.53%)

BofA analyst Jason…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ALKS Alkermes
$32.09 /

+0.17 (+0.53%)

ALKS Alkermes
$32.09 /

+0.17 (+0.53%)

09/10/21 Mizuho
Alkermes price target raised to $36 from $33 at Mizuho
09/02/21
Fly Intel: Top five analyst downgrades
09/02/21 BofA
BofA downgrades Alkermes to Underperform on valuation after 56% rally
09/02/21 BofA
Alkermes downgraded to Underperform from Neutral at BofA
ALKS Alkermes
$32.09 /

+0.17 (+0.53%)

ALKS Alkermes
$32.09 /

+0.17 (+0.53%)

Hot Stocks
Cathie Wood's ARK Investment bought about 68K shares of Peloton on Friday  06:33
09/27/21
09/27
06:33
09/27/21
06:33
PTON

Peloton

$92.67 /

-1.66 (-1.76%)

 
ShowHide Related Items >><<
PTON Peloton
$92.67 /

-1.66 (-1.76%)

PTON Peloton
$92.67 /

-1.66 (-1.76%)

09/13/21 Goldman Sachs
Peloton initiated with a Neutral at Goldman Sachs
09/10/21 BofA
Affirm price target raised to $119 from $82 at BofA
09/10/21 DA Davidson
Affirm price target raised to $110 from $85 at DA Davidson
09/09/21 JPMorgan
Netflix, Uber added as top U.S. Internet picks at JPMorgan
PTON Peloton
$92.67 /

-1.66 (-1.76%)

PTON Peloton
$92.67 /

-1.66 (-1.76%)

PTON Peloton
$92.67 /

-1.66 (-1.76%)

PTON Peloton
$92.67 /

-1.66 (-1.76%)

Hot Stocks
Cathie Wood's ARK Investment bought about 805K shares of Invitae on Friday  06:33
09/27/21
09/27
06:33
09/27/21
06:33
NVTA

Invitae

$30.06 /

-2.125 (-6.60%)

 
ShowHide Related Items >><<
NVTA Invitae
$30.06 /

-2.125 (-6.60%)

NVTA Invitae
$30.06 /

-2.125 (-6.60%)

08/04/21 Benchmark
Invitae upgraded to Buy from Hold at Benchmark
06/21/21 Wells Fargo
Invitae price target raised to $35 from $30 at Wells Fargo
06/15/21 Raymond James
Invitae initiated with an Outperform at Raymond James
06/15/21 Raymond James
Invitae initiated with an Outperform at Raymond James
NVTA Invitae
$30.06 /

-2.125 (-6.60%)

  • 22
    Jan
NVTA Invitae
$30.06 /

-2.125 (-6.60%)

NVTA Invitae
$30.06 /

-2.125 (-6.60%)

NVTA Invitae
$30.06 /

-2.125 (-6.60%)

Hot Stocks
Synlogic appoints Molly Harper as chief business officer » 06:32
09/27/21
09/27
06:32
09/27/21
06:32
SYBX

Synlogic

$3.18 /

+0.03 (+0.95%)

, RLMD

Relmada Therapeutics

$28.99 /

-0.44 (-1.50%)

Synlogic (SYBX) announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SYBX Synlogic
$3.18 /

+0.03 (+0.95%)

RLMD Relmada Therapeutics
$28.99 /

-0.44 (-1.50%)

SYBX Synlogic
$3.18 /

+0.03 (+0.95%)

09/20/21 Chardan
Synlogic phenylketonuria data 'encouraging,' says Chardan
09/20/21 Piper Sandler
Synlogic price target raised to $9 at Piper Sandler on positive SynPHEny data
07/09/21 Chardan
Synlogic assumed with a Buy at Chardan
06/28/21 H.C. Wainwright
Synlogic price target lowered to $9 from $13 at H.C. Wainwright
RLMD Relmada Therapeutics
$28.99 /

-0.44 (-1.50%)

07/28/21 Truist
Relmada Therapeutics price target raised to $90 from $75 at Truist
07/27/21 Goldman Sachs
Relmada Therapeutics' positive data removes overhang, says Goldman Sachs
07/27/21 SVB Leerink
Relmada Therapeutics shares could move into $35-$40 range, says SVB Leerink
07/27/21 Truist
Relmada Therapeutics price target raised to $90 from $75 at Truist
SYBX Synlogic
$3.18 /

+0.03 (+0.95%)

RLMD Relmada Therapeutics
$28.99 /

-0.44 (-1.50%)

  • 23
    Sep
  • 16
    Apr
SYBX Synlogic
$3.18 /

+0.03 (+0.95%)

RLMD Relmada Therapeutics
$28.99 /

-0.44 (-1.50%)

Hot Stocks
Babcock & Wilcox unit awarded $35M contract » 06:31
09/27/21
09/27
06:31
09/27/21
06:31
BW

Babcock & Wilcox

$6.02 /

-0.29 (-4.60%)

Babcock & Wilcox…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BW Babcock & Wilcox
$6.02 /

-0.29 (-4.60%)

BW Babcock & Wilcox
$6.02 /

-0.29 (-4.60%)

03/25/21
Fly Intel: Top five analyst initiations
03/25/21 Lake Street
Babcock & Wilcox initiated with a Buy at Lake Street
03/25/21 DA Davidson
Babcock & Wilcox initiated with a Buy at DA Davidson
02/18/21
Fly Intel: Top five analyst initiations
BW Babcock & Wilcox
$6.02 /

-0.29 (-4.60%)

  • 10
    Feb
BW Babcock & Wilcox
$6.02 /

-0.29 (-4.60%)

Recommendations
Lordstown Motors price target lowered to $10 from $20 at BTIG » 06:31
09/27/21
09/27
06:31
09/27/21
06:31
RIDE

Lordstown Motors

$7.57 /

+0.125 (+1.68%)

BTIG analyst Gregory…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
RIDE Lordstown Motors
$7.57 /

+0.125 (+1.68%)

RIDE Lordstown Motors
$7.57 /

+0.125 (+1.68%)

09/26/21 Goldman Sachs
Lordstown Motors downgraded to Sell from Neutral at Goldman Sachs
09/16/21 BofA
BofA cuts Lordstown Motors to Underperform, halves price target to $5
09/16/21 BofA
Lordstown Motors downgraded to Underperform from Neutral at BofA
08/12/21 RBC Capital
Lordstown Motors price target lowered to $1 from $5 at RBC Capital
RIDE Lordstown Motors
$7.57 /

+0.125 (+1.68%)

RIDE Lordstown Motors
$7.57 /

+0.125 (+1.68%)

RIDE Lordstown Motors
$7.57 /

+0.125 (+1.68%)

RIDE Lordstown Motors
$7.57 /

+0.125 (+1.68%)

Recommendations
Acceleron price target raised to $179 from $113 at RBC Capital » 06:27
09/27/21
09/27
06:27
09/27/21
06:27
XLRN

Acceleron

$167.52 /

+7.86 (+4.92%)

, BMY

Bristol-Myers

$60.23 /

-0.395 (-0.65%)

RBC Capital analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
XLRN Acceleron
$167.52 /

+7.86 (+4.92%)

BMY Bristol-Myers
$60.23 /

-0.395 (-0.65%)

XLRN Acceleron
$167.52 /

+7.86 (+4.92%)

08/05/21 Piper Sandler
Acceleron price target raised to $146 from $143 at Piper Sandler
07/19/21 Wolfe Research
Acceleron assumed with an Outperform at Wolfe Research
06/24/21 Oppenheimer
Acceleron price target raised to $160 from $141 at Oppenheimer
06/11/21 H.C. Wainwright
Acceleron results for Phase 2 BEYOND study 'impressive,' says H.C. Wainwright
BMY Bristol-Myers
$60.23 /

-0.395 (-0.65%)

09/20/21 Citi
Citi says 'remain upbeat' on Pfizer Covid revenue despite mixed panel vote
09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
07/27/21 Mizuho
Bristol-Myers deal a positive signal about BridgeBio's BBP-398, says Mizuho
07/26/21 Truist
Bristol-Myers assumed with a Buy at Truist
XLRN Acceleron
$167.52 /

+7.86 (+4.92%)

BMY Bristol-Myers
$60.23 /

-0.395 (-0.65%)

XLRN Acceleron
$167.52 /

+7.86 (+4.92%)

BMY Bristol-Myers
$60.23 /

-0.395 (-0.65%)

BMY Bristol-Myers
$60.23 /

-0.395 (-0.65%)

BMY Bristol-Myers
$60.23 /

-0.395 (-0.65%)

Recommendations
CarGurus price target raised to $59 from $46 at Benchmark » 06:26
09/27/21
09/27
06:26
09/27/21
06:26
CARG

CarGurus

$32.81 /

+0.83 (+2.60%)

Benchmark analyst Daniel…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
CARG CarGurus
$32.81 /

+0.83 (+2.60%)

CARG CarGurus
$32.81 /

+0.83 (+2.60%)

08/26/21
Fly Intel: Top five analyst upgrades
08/26/21 RBC Capital
CarGurus upgraded to Outperform from Sector Perform at RBC Capital
08/12/21 Needham
CarGurus upgraded to Buy at Needham, sees stock close to bottom
08/12/21 Needham
CarGurus upgraded to Buy from Hold at Needham
CARG CarGurus
$32.81 /

+0.83 (+2.60%)

CARG CarGurus
$32.81 /

+0.83 (+2.60%)

Periodicals
GM to penalize employees who haven't reported vaccination status, WSJ reports » 06:25
09/27/21
09/27
06:25
09/27/21
06:25
GM

General Motors

$52.22 /

+0.31 (+0.60%)

General Motors has begun…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
GM General Motors
$52.22 /

+0.31 (+0.60%)

GM General Motors
$52.22 /

+0.31 (+0.60%)

09/26/21 Goldman Sachs
General Motors price target lowered to $59 from $62 at Goldman Sachs
09/24/21 Citi
GM investor day could be 'significant positive catalyst,' says Citi
09/13/21 Barclays
General Motors price target lowered to $68 from $71 at Barclays
08/09/21 Jefferies
General Motors price target lowered to $53 from $68 at Jefferies
GM General Motors
$52.22 /

+0.31 (+0.60%)

GM General Motors
$52.22 /

+0.31 (+0.60%)

GM General Motors
$52.22 /

+0.31 (+0.60%)

GM General Motors
$52.22 /

+0.31 (+0.60%)

Periodicals
Acceleron in advanced talks to be acquired for about $180/share, Bloomberg says » 06:22
09/27/21
09/27
06:22
09/27/21
06:22
XLRN

Acceleron

$167.52 /

+7.86 (+4.92%)

Acceleron is in advanced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
XLRN Acceleron
$167.52 /

+7.86 (+4.92%)

XLRN Acceleron
$167.52 /

+7.86 (+4.92%)

08/05/21 Piper Sandler
Acceleron price target raised to $146 from $143 at Piper Sandler
07/19/21 Wolfe Research
Acceleron assumed with an Outperform at Wolfe Research
06/24/21 Oppenheimer
Acceleron price target raised to $160 from $141 at Oppenheimer
06/11/21 H.C. Wainwright
Acceleron results for Phase 2 BEYOND study 'impressive,' says H.C. Wainwright
XLRN Acceleron
$167.52 /

+7.86 (+4.92%)

XLRN Acceleron
$167.52 /

+7.86 (+4.92%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.